167 related articles for article (PubMed ID: 35567430)
21. Prostate Health Index density improves detection of clinically significant prostate cancer.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
[TBL] [Abstract][Full Text] [Related]
22. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
23. Re-thinking How We Use Prostate Health Index for African American Men.
Morris KE; Kotamarti S; Polascik TJ; Moul JW
Urology; 2023 May; 175():144-150. PubMed ID: 36828263
[TBL] [Abstract][Full Text] [Related]
24. Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection.
Chiu ST; Cheng YT; Pu YS; Lu YC; Hong JH; Chung SD; Chiang CH; Huang CY
Front Oncol; 2021; 11():772182. PubMed ID: 34869007
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Role of Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer in Biopsy-Naïve Men: A Meta-Analysis.
Tu X; Liu Z; Zhang C; Chang T; Xu H; Bao Y; Li J; Jin K; Yuan Q; Qiu S; Yang L; Wei Q
Urol Int; 2020; 104(3-4):187-198. PubMed ID: 31825927
[TBL] [Abstract][Full Text] [Related]
26. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
[TBL] [Abstract][Full Text] [Related]
27. Construction and Comparison of Different Models in Detecting Prostate Cancer and Clinically Significant Prostate Cancer.
Zhou Y; Qi W; Cui J; Zhong M; Lv G; Qu S; Chen S; Li R; Shi B; Zhu Y
Front Oncol; 2022; 12():911725. PubMed ID: 35903679
[TBL] [Abstract][Full Text] [Related]
28. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
[TBL] [Abstract][Full Text] [Related]
29. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Woo S; Suh CH; Eastham JA; Zelefsky MJ; Morris MJ; Abida W; Scher HI; Sidlow R; Becker AS; Wibmer AG; Hricak H; Vargas HA
Eur Urol Oncol; 2019 Nov; 2(6):605-616. PubMed ID: 31204311
[TBL] [Abstract][Full Text] [Related]
31. Beyond PSA: The Role of Prostate Health Index (phi).
Ferro M; De Cobelli O; Lucarelli G; Porreca A; Busetto GM; Cantiello F; Damiano R; Autorino R; Musi G; Vartolomei MD; Muto M; Terracciano D
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053990
[TBL] [Abstract][Full Text] [Related]
32. Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.
Chen H; Qian Y; Wu Y; Shi B; Zhou J; Qu F; Gu Z; Ding J; Yu Y
Front Oncol; 2022; 12():864111. PubMed ID: 35463344
[TBL] [Abstract][Full Text] [Related]
33. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
34. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
35. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy.
Wang CB; Chen SH; Zhao L; Jin X; Chen X; Ji J; Mo ZN; Wang FB
Clin Transl Oncol; 2023 Mar; 25(3):758-767. PubMed ID: 36266386
[TBL] [Abstract][Full Text] [Related]
36. Performance of Multiparametric MRI of the Prostate in Biopsy Naïve Men: A Meta-analysis of Prospective Studies.
Becerra MF; Alameddine M; Zucker I; Tamariz L; Palacio A; Nemeth Z; Velasquez MC; Savio LF; Panizzutti M; Jue JS; Soodana-Prakash N; Ritch CR; Gonzalgo ML; Parekh DJ; Punnen S
Urology; 2020 Dec; 146():189-195. PubMed ID: 32890616
[TBL] [Abstract][Full Text] [Related]
37. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
38. Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4-10 ng/mL.
Hsieh PF; Chang CH; Yang CR; Huang CP; Chen WC; Yeh CC; Chou EC; Chen KL; Lien CS; Chen GH; Hsiao PJ; Chang YH; Wu HC
Kaohsiung J Med Sci; 2018 Aug; 34(8):461-466. PubMed ID: 30041764
[TBL] [Abstract][Full Text] [Related]
39. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
[TBL] [Abstract][Full Text] [Related]
40. Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study.
Liu AQ; Remmers S; Lau SY; Yip SY; Leung CH; Mak CW; Yee CH; Teoh JY; Hou SM; Roobol M; Ng CF; Chiu PK
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):684-689. PubMed ID: 34453109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
